Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,404
Out of 5,154 analysts
8
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: In-Line | $73 → $110 | $96.00 | +14.58% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $38.63 | +24.26% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $10.95 | +173.97% | 2 | Mar 22, 2023 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $28.43 | +40.70% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.60 | +3,749.37% | 1 | May 25, 2021 |
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $96.00
Upside: +14.58%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $38.63
Upside: +24.26%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $10.95
Upside: +173.97%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $28.43
Upside: +40.70%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.60
Upside: +3,749.37%